Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

Pasireotide has a broader somatostatin receptor binding profile than other somatostatin analogues. A 16-week, Phase II trial showed that pasireotide may be an effective treatment for acromegaly. An extension to this trial assessed the long-term efficacy and safety of pasireotide. This study was an o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Petersenn, Stephan, Farrall, Andrew J., Block, Christophe, Melmed, Shlomo, Schopohl, Jochen, Caron, Philippe, Cuneo, Ross, Kleinberg, David, Colao, Annamaria, Ruffin, Matthieu, Hermosillo Reséndiz, Karina, Hughes, Gareth, Hu, Ke, Barkan, Ariel
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3942632/
https://ncbi.nlm.nih.gov/pubmed/23529827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11102-013-0478-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados